Package Insert: Information for the Patient

Privenax 150 mg Hard Capsules EFG

dabigatrán etexilate

Read this package insert carefully before starting to take this medicine, as it contains important information for you.

• Keep this package insert, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package insert. See section 4.

This medication contains the active ingredient dabigatrán etexilate and belongs to a group of medications called anticoagulants. It works by blocking a substance in the body involved in the formation of blood clots.

Dabigatrán is used in adults for:

• preventing the formation of blood clots in the brain (stroke) and in other blood vessels of the body if you have a type of irregular heart rhythm called non-valvular atrial fibrillation and have at least one additional risk factor.

• treat blood clots in the veins of your legs and lungs and to prevent new blood clots from forming in the veins of your legs and lungs.

Dabigatrán is used in children for:

• treat blood clots and to prevent new blood clots from forming.

Do not take Privenax

• if you are allergic to dabigatrán etexilato or any of the other components of this medication (listed in section 6).
• if your renal function is severely reduced.
• if you currently have bleeding.
• if you have any organ disease in the body that increases the risk of severe bleeding (e.g., stomach ulcer, head injury or bleeding, recent brain or eye surgery).
• if you are prone to bleeding. This tendency may be congenital, of unknown cause, or caused by other medications.
• if you are taking medications to prevent blood clotting in the blood (e.g., warfarin, rivaroxabán, apixabán, or heparin), except when changing anticoagulant treatment, while having a venous or arterial catheter, and heparin is administered through this catheter to keep it open, or while your normal heart rhythm is being restored through a procedure called catheter ablation for atrial fibrillation.
• if your liver function is severely reduced or you have any liver disease that may be fatal.
• if you are taking ketoconazol oral or itraconazol, medications used in the treatment of fungal infections.
• if you are taking ciclosporina oral, a medication used to prevent organ rejection after a transplant.
• if you are taking dronedarona, a medication used to treat abnormal heart rhythm.
• if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medication used to treat hepatitis C.
• if you have had a heart valve artificial implanted that requires permanent anticoagulant treatment.

Warnings and precautions

Consult your doctor before starting to take dabigatrán. During treatment with this medication, you may also need to consult your doctor if you experience any symptoms or if you are to undergo surgery.

Inform your doctorif you have or have had any disorder or disease, especially any of the following:

• if you have an increased risk of bleeding, for example:
• • if you have recently had bleeding.
  • if you have had a surgical tissue extraction (biopsy) in the last month.
  • if you have had a severe injury (e.g., a bone fracture, a head injury, or any injury that required surgical treatment).
  • if you have esophageal or stomach inflammation.
  • if you have gastroesophageal reflux disease.
  • if you are taking medications that may increase the risk of bleeding. See “Other medications and dabigatrán” below.
  • if you are taking anti-inflammatory medications such as diclofenaco, ibuprofeno, or piroxicam.
  • if you have a bacterial heart infection (endocarditis).
  • if you know that you have reduced kidney function or if you are dehydrated (symptoms include feeling thirsty and passing small amounts of dark-colored, concentrated urine with foam).
  • if you are over 75 years old.
  • if you are an adult and weigh 50 kg or less.
  • only if used in children: if the child has a brain infection or around the brain.

• if you have had a heart attack or if you have been diagnosed with diseases that increase the risk of having a heart attack.

• if you have liver disease associated with changes in blood tests. The use of dabigatrán is not recommended in this case.

Be especially careful with dabigatrán

• if you have to undergo surgery:

In this case, dabigatrán should be temporarily interrupted due to a higher risk of bleeding during and shortly after surgery. It is very important that you take dabigatrán exactly as your doctor has instructed you before and after surgery.

• if a surgical procedure requires the placement of a catheter or injection in the spine (e.g., for epidural or spinal anesthesia or for pain relief):
• • It is very important that you take dabigatrán exactly as your doctor has instructed you before and after surgery.
  • Inform your doctor immediately if you experience numbness or weakness in your legs or intestinal or urinary problems after the end of anesthesia, as this situation requires urgent attention.

• if you fall or are injured during treatment, especially if you hit your head. Seek urgent medical attention. You may need a doctor to examine you, as you may have a higher risk of bleeding.

• if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that increases the risk of blood clots), inform your doctor so that they can decide if your treatment needs to be modified.

Other medications and dabigatrán

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.Particularly, you must inform your doctor before taking dabigatrán if you are taking any of the following medications:

• Medications to reduce blood clotting (e.g., warfarin, fenprocumón, acenocumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxabán, acetylsalicylic acid)
• Medications for the treatment of fungal infections (e.g., ketoconazol, itraconazol), except when applied to the skin.
• Medications used in the treatment of abnormal heart rhythm (e.g., amiodarona, dronedarona, quinidina, verapamilo)

If you are taking medications that contain verapamilo, your doctor may instruct you to use a reduced dose of dabigatrán according to the disease for which you have been prescribed it. See section 3.

• Medications for the prevention of organ rejection after a transplant (e.g., tacrólimus, ciclosporina)
• A combination product of glecaprevir and pibrentasvir (an antiviral medication used to treat hepatitis C)
• Anti-inflammatory and pain-relieving medications (e.g., acetylsalicylic acid, ibuprofeno, diclofenaco)
• St. John's Wort, a medicinal plant for depression
• Antidepressant medications called selective serotonin reuptake inhibitors or selective serotonin and norepinephrine reuptake inhibitors
• Rifampicina or claritromicina (two antibiotics)

• Medications for HIV/AIDS (e.g., ritonavir)
• Certain medications for the treatment of epilepsy (e.g., carbamazepina, fenitoína)

Pregnancy and breastfeeding

The effects of dabigatrán on pregnancy and the fetus are unknown. Do not use dabigatrán if you are pregnant unless your doctor tells you it is safe to do so. If you are of childbearing age, avoid becoming pregnant during treatment with this medication.

Do not breastfeed naturally during treatment with dabigatrán.

Driving and operating machinery

Dabigatrán has no known effects on the ability to drive and operate machinery.

Privenax capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole.

Follow exactly the administration instructions of this medication as indicated by your doctor. If in doubt, consult your doctor again.

Take this medication as recommended for the following situations:

Prevention of cerebral or systemic vascular occlusion due to blood clot formationdeveloped after abnormal heart rhythm and treatment of blood clots in the veins ofyour legs and lungs, including prevention of blood clots from reappearing in the veins of your legs and lungs

The recommended dose is 300 mg administered in the form ofone 150 mg capsule twice a day.

If you are80 years of age or older, the recommended dose of dabigatran is 220 mg administered in the form ofone 110 mg capsule twice a day.

If you are usingmedications containing verapamil, you should be instructed on a reduced dose of dabigatran of 220 mg taken in the form ofone 110 mg capsule twice a day, as your risk of bleeding may increase.

If you have apotential greater risk of bleeding, your doctor may decide to prescribe a dose of dabigatran of 220 mg administered in the form ofone 110 mg capsule twice a day.

You can continue taking this medication as needed to restore your normal heart rhythm through a procedure called cardioversion or through a procedure called catheter ablation for atrial fibrillation. Take dabigatran as instructed by your doctor.

If you have had a medical device (vascular endoprosthesis) placed in a blood vessel to keep it open in a procedure called percutaneous coronary intervention with endoprosthesis placement, you may receive treatment with dabigatran once your doctor has decided that normal blood coagulation control has been achieved. Take dabigatran as instructed by your doctor.

Treatment of blood clots and prevention of blood clots from reappearing inchildren

Dabigatran should be taken twice a day, one dose in the morning and one dose in the evening, approximately at the same time every day. The administration interval should be as close as possible to 12 hours.

The recommended dose depends on age and weight. Your doctor will determine the correct dose. Your doctor may adjust the dose during treatment. Continue using all other medications unless your doctor tells you to stop using one.

Table 1 shows the single doses and total daily doses of dabigatran in milligrams (mg). The doses depend on the patient's weight in kilograms (kg) and age in years.

Table 1: Dosage table for Privenax capsules:

Single doses requiring combinations of more than one capsule:

300 mg:two 150 mg capsules or

four 75 mg capsules

260 mg:one 110 mg capsule plus one 150 mg capsule or

one 110 mg capsule plus two 75 mg capsules

220 mg:two 110 mg capsules

185 mg:one 75 mg capsule plus one 110 mg capsule

150 mg:one 150 mg capsule or

two 75 mg capsules

How to take Privenax

Privenax can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure release in the stomach. Do not break, chew, or open the capsule to take only its contents, as this may increase the risk of bleeding.

Instructions for opening the blisters

The following images illustrate how to extract the Privenax capsules from the blister:

1

Separate an individual blister from the blister strip through the perforated line.

2

Remove the rear sheet and extract the capsule.

• Do not press the capsules through the blister sheet.
• Do not remove the blister sheet until the capsule is needed.

Change in anticoagulant treatment

Do not change your anticoagulant treatment without specific instructions from your doctor.

If you take more Privenax than you should

Taking too much Privenax increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules of this medication. There are specific treatment options available.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, Teléfono 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take Privenax

A missed dose can be taken up to 6 hours before the next dose.

A missed dose should be omitted if the remaining time before the next dose is less than 6 hours. Do not take a double dose to compensate for missed doses.

If you interrupt treatment with Privenax

TakePrivenax exactly as prescribed. Do not interrupt your treatment with Privenax without consulting your doctor first, as the risk of developing a blood clot may be greater if you interrupt treatment too soon. Contact your doctor if you experience indigestion after taking this medication.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

Dabigatrán acts on blood coagulation; therefore, most side effects are related to signs such as bruising or bleeding. Severe or life-threatening bleeding episodes may occur, which can cause disability, be potentially fatal, or even lead to death. In some cases, these bleeding episodes may not be evident.

If you experience any bleeding episode that does not stop on its own or if you experience signs of excessive bleeding (exceptional weakness, fatigue, pallor, dizziness, headache, or unexplained swelling), consult your doctor immediately. Your doctor may decide to keep you under close observation or change your medication.

Inform your doctor immediately if you experience a severe allergic reaction that causes difficulty breathing or dizziness.

The possible side effects are listed below, grouped by frequency of occurrence.

Prevention of cerebral or systemic vascular occlusion by blood clot formation developed after abnormal heart rhythm

Frequent (may affect up to 1 in 10 people):

• Bleeding may occur from the nose, stomach, or intestines, penis/vagina, or urinary tract (including blood in the urine that turns the urine pink or red), or under the skin
• Decreased number of red blood cells in the blood
• Abdominal pain or stomach pain
• Indigestion
• Frequent loose or liquid stools
• Feeling like vomiting

Rare (may affect up to 1 in 100 people):

• Bleeding
• Bleeding may occur from hemorrhoids, rectum, or brain
• Formation of hematomas
• Coughing up blood or sputum with blood spots
• Decreased number of platelets in the blood
• Decreased hemoglobin level in the blood (the substance present in red blood cells)
• Allergic reaction
• Sudden change in skin that affects color and physical appearance
• Itching
• Ulcer in the stomach or intestines (including esophageal ulcer)
• Inflammation of the esophagus and stomach
• Reflux of stomach acid into the esophagus
• Vomiting
• Difficulty swallowing
• Anomalies in liver function tests

Rare (may affect up to 1 in 1,000 people):

• Bleeding may occur in a joint, surgical incision site, wound, injection site, or venous catheter site
• Severe allergic reaction that causes difficulty breathing or dizziness
• Severe allergic reaction that causes facial or throat swelling
• Urticaria with dark, prominent, and itchy red bumps, caused by an allergic reaction
• Decreased proportion of blood cells
• Increased liver enzymes
• Yellowing of the skin or white of the eyes, caused by liver or blood disorders

Unknown frequency (frequency cannot be estimated from available data):

• Difficulty breathing or wheezing
• Decreased number or even absence of leukocytes (which help fight infections)
• Hair loss

In a clinical trial, the incidence of heart attacks with dabigatrán was numerically higher than with warfarin. The global incidence was low.

Treatment of blood clots in the veins of your legs and lungs, including prevention of recurring blood clots in the veins of your legs and/or lungs

Frequent (may affect up to 1 in 10 people):

• Bleeding may occur from the nose, stomach, or intestines, rectum, penis/vagina, or urinary tract (including blood in the urine that turns the urine pink or red), or under the skin
• Indigestion

Rare (may affect up to 1 in 100 people):

• Bleeding
• Bleeding may occur in a joint or wound
• Bleeding may occur from hemorrhoids
• Decreased number of red blood cells in the blood
• Formation of hematomas
• Coughing up blood or sputum with blood spots
• Allergic reaction
• Sudden change in skin that affects color and physical appearance
• Itching
• Ulcer in the stomach or intestines (including esophageal ulcer)
• Inflammation of the esophagus and stomach
• Reflux of stomach acid into the esophagus
• Feeling like vomiting
• Vomiting
• Abdominal pain or stomach pain
• Frequent loose or liquid stools
• Anomalies in liver function tests
• Increased liver enzymes

Rare (may affect up to 1 in 1,000 people):

• Bleeding may occur in a surgical incision site, injection site, or venous catheter site, or from the brain
• Decreased number of platelets in the blood
• Severe allergic reaction that causes difficulty breathing or dizziness
• Severe allergic reaction that causes facial or throat swelling
• Urticaria with dark, prominent, and itchy red bumps, caused by an allergic reaction
• Difficulty swallowing

Unknown frequency (frequency cannot be estimated from available data):

• Difficulty breathing or wheezing
• Decreased hemoglobin level in the blood (the substance present in red blood cells)
• Decreased proportion of blood cells
• Decreased number or even absence of leukocytes (which help fight infections)
• Yellowing of the skin or white of the eyes, caused by liver or blood disorders
• Hair loss

In the clinical trial program, the incidence of heart attacks with dabigatrán was higher than with warfarin. The global incidence was low. No imbalance in the incidence of heart attacks was observed in patients treated with dabigatrán compared to patients treated with placebo.

Treatment of blood clots and prevention of recurring blood clots in children

Frequent (may affect up to 1 in 10 people):

• Decreased number of red blood cells in the blood
• Decreased number of platelets in the blood
• Urticaria with dark, prominent, and itchy red bumps, caused by an allergic reaction
• Sudden change in skin that affects color and physical appearance
• Formation of hematomas
• Nasal bleeding
• Reflux of stomach acid into the esophagus
• Vomiting
• Feeling like vomiting
• Frequent loose or liquid stools
• Indigestion
• Hair loss
• Increased liver enzymes

Rare (may affect up to 1 in 100 people):

• Decreased number of leukocytes (which help fight infections)
• Bleeding may occur from the stomach or intestines, brain, rectum, penis/vagina, or urinary tract (including blood in the urine that turns the urine pink or red), or under the skin
• Decreased hemoglobin level in the blood (the substance present in red blood cells)
• Decreased proportion of blood cells
• Itching
• Coughing up blood or sputum with blood spots
• Abdominal pain or stomach pain
• Inflammation of the esophagus and stomach
• Allergic reaction
• Difficulty swallowing
• Yellowing of the skin or white of the eyes, caused by liver or blood disorders

Unknown frequency (frequency cannot be estimated from available data):

• Decreased leukocytes (which help fight infections)
• Severe allergic reaction that causes difficulty breathing or dizziness
• Severe allergic reaction that causes facial or throat swelling
• Difficulty breathing or wheezing
• Bleeding
• Bleeding may occur in a joint or wound, surgical incision site, injection site, or venous catheter site
• Bleeding may occur from hemorrhoids
• Ulcer in the stomach or intestines (including esophageal ulcer)
• Anomalies in liver function tests

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the box or blister pack after “CAD”. The expiration date is the last day of the month indicated.

Do not store above 86°F (30°C)

Store in the original packaging to protect it from moisture.

Medications should not be disposed of through drains or trash. Dispose of containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.

Composition of Privenax

• The active ingredient is dabigatrán. Each hard capsule contains 150 mg of dabigatrán etexilate (in the form of mesilate).
• The other components are tartaric acid, gum arabic, hypromellose 2910, dimethicone 350, talc, and hydroxypropylcellulose.
• The capsule coating contains carrageenan, potassium chloride, titanium dioxide (E-171), hypromellose, and FD&C Blue 2/Indigo Carmine (E-132).

Appearance of the product and content of the container

Privenax 150 mg are pale yellow to white pellets inside hard gelatin capsules, size 0, with a blue cap and a white or off-white body.

Privenax is presented in containers containing 10 x 1, 60 x 1 hard gelatin capsules in perforated aluminum/OPA-AL-PVC blisters.

Only some container sizes may be commercially available.

Marketing Authorization Holder

Kern Pharma S.L.

Venus, 72 – Pol. Ind. Colón II

08228 Terrassa - Barcelona

Spain

Responsible for manufacturing

Galenicum Health, S.L.U.

Sant Gabriel, 50

08950 – Esplugues de Llobregat (Barcelona)

Spain

or

Galenicum Health, S.L.

Avenida Cornella, 144 Edificio LEKLA

08950 – Esplugues de Llobregat (Barcelona)

Spain

or

SAG Manufacturing S.L.U

Crta. N-I, Km 36

28750 San Agustin de Guadalix,

Madrid –Spain

This medicinal productis authorized in the member states of the European Economic Area with the following names:

Malta – Privenax 150 mg hard capsules

Portugal – Dabigatrano etexilate Pharmakern 150 mg capsules

Spain – Privenax 150 mg hard capsules EFG

Revision date of this leaflet:June 2024

The most recent and detailed information about this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS):http://www.aemps.gob.es/.